Axsome Therapeutics Inc (AXSM.OQ)
2.55USD
20 Apr 2018
-- (--)
$2.55
--
--
--
--
56,014
$6.45
$2.05
BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
* AXSOME THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2 CLINICAL TRIAL OF AXS-05 IN SMOKING CESSATION Source text for Eikon: Further company coverage:
BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
* AXSOME THERAPEUTICS APPOINTS NICK PIZZIE, CPA, MBA, AS CHIEF FINANCIAL OFFICER
BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31
* AXSOME THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial
* AXSOME THERAPEUTICS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 1 TRIAL OF NEXT GENERATION PRODUCT CANDIDATE AXS-09 CONTAINING CHIRALLY PURE ESBUPROPION AND DEXTROMETHORPHAN
BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial
* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL
BRIEF-Sabby Management Reports A 5.52 Percent Passive Stake In Axsome Therapeutics
* SABBY MANAGEMENT, LLC REPORTS A 5.52 PERCENT PASSIVE STAKE IN AXSOME THERAPEUTICS INC AS OF DEC 1 - SEC FILING Source text : [http://bit.ly/2jNkBHB] Further company coverage:
BRIEF-Axsome Therapeutics Announces AXS-07 For The Treatment Of Migraine
* AXSOME THERAPEUTICS ANNOUNCES AXS-07 FOR THE TREATMENT OF MIGRAINE
BRIEF-Axsome Therapeutics reports Q3 loss per share $0.27
* Axsome Therapeutics reports third quarter 2017 financial results